Industry
Medical - Diagnostics & Research
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Loading...
Open
6.07
Mkt cap
8.6M
Volume
39K
High
6.30
P/E Ratio
-3.22
52-wk high
7.30
Low
5.72
Div yield
N/A
52-wk low
4.31
Portfolio Pulse from
November 18, 2024 | 11:30 pm
Portfolio Pulse from Benzinga Newsdesk
October 08, 2024 | 2:04 pm
Portfolio Pulse from Benzinga Newsdesk
July 25, 2024 | 1:09 pm
Portfolio Pulse from Benzinga Newsdesk
July 17, 2024 | 6:45 pm
Portfolio Pulse from Benzinga Newsdesk
July 17, 2024 | 1:21 pm
Portfolio Pulse from Benzinga Newsdesk
June 12, 2024 | 1:04 pm
Portfolio Pulse from Benzinga Newsdesk
February 13, 2024 | 3:04 pm
Portfolio Pulse from Benzinga Newsdesk
February 06, 2024 | 3:04 pm
Portfolio Pulse from Benzinga Newsdesk
February 06, 2024 | 3:00 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.